Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of golcadomide plus rituximab versus investigator's choice in relapsed or refractory follicular lymphoma
CTR20253038Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of golcadomide, rituximab in follicular lymphoma (FL), sponsored by Celgene Corporation. Started Jul 2025; status: active.
02
Drugs
golcadomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20253038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253038.